Investigation of Vasodilation and Intensity of Headache Triggered by Glucagon Like Peptide-1 in Humans

Investigation of Vasodilation and Intensity of Headache Triggered by Glucagon-like Peptide-1 in Healthy Volunteers and Migraine Patients

Studying glucagon-like peptide-1 (GLP-1) induced vasodilatory effects on extra - and intracerebral arteries and headache in healthy volunteers and migraine patients without aura.

The purpose of this study is to examine the association between vasodilation and intensity of headache triggered by glucagon-like peptide 1 (GLP-1) in healthy volunteers and migraine patients without aura.

Criteria for the healthy volunteers group

Inclusion Criteria:

• Healthy men/women.
• Age 18 to 60 years old.
• Weight 50 to 100 kg.

Exclusion Criteria:

• Tension headache more than 5 days a month in the preceding year.
• All other primary headache types.
• Headache on the examination day or within 48 hours before infusion of the study drug.
• Smoking.
• Daily intake of medicine of any kind except for peroral contraceptives.
• Women, who on the day of examination is 2 days before or 3 days from the first day of bleeding.
• Hypertension or hypotension.
• Coronary heart disease of any kind, as well as cerebrovascular disease.
• Pulmonary disease.
• Allergy to contents in the study drug.
• Psychiatric disease or substance abuse.
• Disease of any kind which the examining doctor deems relevant for participation in the study.
• Renouncing the right to information concerning own health.

Criteria for the migraine patients group

Inclusion Criteria:

• Migraine patients, who fulfill the ICHD-3 criteria for migraine without aura.
• Age 18 to 60 years old.
• Weight 50 to 100 kg.

Exclusion Criteria:

• Tension headache more than 5 days a month in the preceding year.
• All other primary headache types.
• Headache on the examination day or within 48 hours before infusion of the study drug.
• Smoking.
• Daily intake of medicine of any kind except for peroral contraceptives.
• Women, who on the day of examination is 2 days before or 3 days from the first day of bleeding.
• Hypertension or hypotension.
• Coronary heart disease of any kind, as well as cerebrovascular disease.
• Pulmonary disease.
• Allergy to contents in the study drug.
• Psychiatric disease or substance abuse.
• Disease of any kind which the examining doctor deems relevant for participation in the study.
• Renouncing the right to information concerning own health.